Literature DB >> 22235818

Refractory hypertension: definition, prevalence, and patient characteristics.

Maria Czarina Acelajado1, Roberto Pisoni, Tanja Dudenbostel, Louis J Dell'Italia, Falynn Cartmill, Bin Zhang, Stacey S Cofield, Suzanne Oparil, David A Calhoun.   

Abstract

Among patients with resistant hypertension (RHTN), there are those whose blood pressure (BP) remains uncontrolled in spite of maximal medical therapy. This retrospective analysis aims to characterize these patients with refractory hypertension. Refractory hypertension was defined as BP that remained uncontrolled after ≥3 visits to a hypertension clinic within a minimum 6-month follow-up period. Of the 304 patients referred for RHTN, 29 (9.5%) remained refractory to treatment. Patients with refractory hypertension and those with controlled RHTN had similar aldosterone levels and plasma renin activity (PRA). Patients with refractory hypertension had higher baseline BP (175±23/97±15 mm Hg vs 158±25/89±15 mm Hg; P=.001/.005) and heart rate, and higher rates of prior stroke and congestive heart failure. During follow-up, the BP of patients with refractory hypertension remained uncontrolled (168.4±14.8/93.8±17.7 mm Hg) in spite of use of an average of 6 antihypertensive medications, while those of patients with controlled RHTN decreased to 129.3±11.2/77.6±10.8 mm Hg. Spironolactone reduced the BP by 12.9±17.8/6.6±13.7 mm Hg in patients with refractory hypertension and by 24.1±16.7/9.2±12.0 mm Hg in patients with controlled RHTN. In patients with RHTN, approximately 10% remain refractory to treatment. Similar aldosterone and PRA levels and a diminished response to spironolactone suggest that aldosterone excess does not explain the treatment failure.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22235818      PMCID: PMC3400427          DOI: 10.1111/j.1751-7176.2011.00556.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  15 in total

1.  Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.

Authors:  B J Gallay; S Ahmad; L Xu; B Toivola; R C Davidson
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.

Authors:  A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

3.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

4.  Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension.

Authors:  Sante D Pierdomenico; Domenico Lapenna; Anna Bucci; Roberta Di Tommaso; Rocco Di Mascio; Bianca M Manente; Maria P Caldarella; Matteo Neri; Franco Cuccurullo; Andrea Mezzetti
Journal:  Am J Hypertens       Date:  2005-11       Impact factor: 2.689

5.  Resistant hypertension: comparing hemodynamic management to specialist care.

Authors:  Sandra J Taler; Stephen C Textor; Jo Ellen Augustine
Journal:  Hypertension       Date:  2002-05       Impact factor: 10.190

6.  Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting.

Authors:  Carrie McAdam-Marx; Xiangyang Ye; Jennifer C Sung; Diana I Brixner; Kristijan H Kahler
Journal:  Clin Ther       Date:  2009-05       Impact factor: 3.393

7.  Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

Authors:  B Strauch; T Zelinka; M Hampf; R Bernhardt; J Widimsky
Journal:  J Hum Hypertens       Date:  2003-05       Impact factor: 3.012

8.  Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Authors:  Krishna K Gaddam; Mari K Nishizaka; Monique N Pratt-Ubunama; Eduardo Pimenta; Inmaculada Aban; Suzanne Oparil; David A Calhoun
Journal:  Arch Intern Med       Date:  2008-06-09

9.  Management of the patient with resistant hypertension.

Authors:  R C Tarazi
Journal:  Hosp Pract (Off Ed)       Date:  1981-01

10.  Prognosis in therapy-resistant hypertension.

Authors:  H Isaksson; J Ostergren
Journal:  J Intern Med       Date:  1994-12       Impact factor: 8.989

View more
  69 in total

1.  Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance.

Authors:  A de la Sierra; D A Calhoun; E Vinyoles; J R Banegas; J J de la Cruz; M Gorostidi; J Segura; L M Ruilope
Journal:  J Hum Hypertens       Date:  2014-01-09       Impact factor: 3.012

Review 2.  Resistant Hypertension: An Update of Experimental and Clinical Findings.

Authors:  Anping Cai; David A Calhoun
Journal:  Hypertension       Date:  2017-05-15       Impact factor: 10.190

3.  Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure.

Authors:  Mohammed Siddiqui; Tanja Dudenbostel; David A Calhoun
Journal:  Can J Cardiol       Date:  2015-07-08       Impact factor: 5.223

Review 4.  Resistant or refractory hypertension: are they different?

Authors:  Rodrigo Modolo; Ana Paula de Faria; Aurélio Almeida; Heitor Moreno
Journal:  Curr Hypertens Rep       Date:  2014-10       Impact factor: 5.369

5.  Resistant hypertension: do all definitions describe the same patients?

Authors:  L Boswell; J Pascual; A Oliveras
Journal:  J Hum Hypertens       Date:  2015-01-15       Impact factor: 3.012

6.  Severe and refractory hypertension in a young woman.

Authors:  René H Cuadra; William B White
Journal:  J Am Soc Hypertens       Date:  2016-04-04

7.  Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Authors:  David A Calhoun; John N Booth; Suzanne Oparil; Marguerite R Irvin; Daichi Shimbo; Daniel T Lackland; George Howard; Monika M Safford; Paul Muntner
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

Review 8.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

9.  Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension.

Authors:  Keisuke Shinohara; Xuebo Liu; Donald A Morgan; Deborah R Davis; Maria Luisa S Sequeira-Lopez; Martin D Cassell; Justin L Grobe; Kamal Rahmouni; Curt D Sigmund
Journal:  Hypertension       Date:  2016-10-17       Impact factor: 10.190

Review 10.  Catheter-based Renal Artery Denervation for Resistant Hypertension: Promise Unfulfilled or Unsettled?

Authors:  Matthew G Denker; Debbie L Cohen; Raymond R Townsend
Journal:  Curr Atheroscler Rep       Date:  2015-10       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.